ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply mutations in BCR/ABL have been also described. In the present rep...
Enregistré dans:
Auteurs principaux: | , , , , , , , , , , , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2009
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3dff57472bb442969456148bb3804193 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Soyez le premier à ajouter un commentaire!